Staniszewska et al. studied the effect of enzalutamide on PSMA expression over a 3-week period in the PSMA-low prostate cancer cell line 22Rv1 and the PSMA-high prostate cancer cell lines C4-2 and LNCaP [39]. The gene discussed is FOLH1; the disease is prostate cancer.